Skip to content

CHECKED

Create an account

Search

Companies

Search companies
Addresses
Company groups
Nearby
Service voucher comparison

People and firms

Directors
Bankruptcy trustees
Notaries

Events

Events: Overview
All events

Company changes

Incorporations
Director changes
Name changes
Registered office moves
Mergers and takeovers

Financial publications

Annual accounts filed
Capital changes
Auditor changes

Legal status & closure

Bankruptcies
Judicial reorganisations
Dissolutions and liquidations
Ex-officio strike-offs
Interim measures

Tools

Tools: Overview

Investigate

Analysis workbench
Compare companies
Sector benchmark
Employer check
Network investigator
Company wealth map

Assess companies

Credit check
Supplier due diligence
AML client file

Market and sector

Sector figures
Municipality map
Subsidies

Invoices and lists

Invoice check
Peppol check
Process a list

Starting out

Name check
Local market research

Lookalike companies
Company as of a date
Permit applications
Creditor guide
Contractor check
Self-check
Public procurement exclusion grounds
Market analysis
Trends
Rankings
Survival tables
Public contracts
Starter mirror
Financial plan

Sign in

NL FR EN

EN

Nederlands Français English

My Checked

Sign in
Create an account

Home / Tools / Value indication / ARCHIDUC USIL

ARCHIDUC USIL: value indication

Sector benchmark
What changed
Value indication

Checked · Insight, alerts and connections for every Belgian company, from official sources.

Based on official Belgian registers and filed annual accounts.

NL FR EN

Discover

All tools Sector figures Rankings Municipality map All events Company groups Trends Survival tables

Checked

About Checked Contact Pricing

Help and guides

Frequently asked questions Knowledge base

Integrations

API AI assistants Excel and Google Sheets Company badge

Legal

Privacy policy Terms of service Cookies

We would like to set cookies. That happens only with your consent. What we measure

Help us improve Checked

If something looks wrong or is missing, please tell us.

Your message Email (optional, only to reply)

Line	Code	2024	2025	Change	%
Total assets	20/58	€3,683,054	€3,676,908	-€6,147	-0.2%
Formation expenses	20	€2,006	€0	-€2,006	-100%
Fixed assets	21/28	€3,209,393	€3,272,359	+€62,965	+2.0%
Intangible fixed assets	21	€452,830	€407,583	-€45,247	-10.0%
Tangible fixed assets	22/27	€2,231,263	€2,339,210	+€107,947	+4.8%
Land and buildings	22	€1,403,705	€1,735,601	+€331,897	+23.6%
Plant, machinery and equipment	23	€825,773	€602,379	-€223,393	-27.1%
Furniture and vehicles	24	€1,785	€1,230	-€556	-31.1%
Financial fixed assets	28	€525,300	€525,565	+€265	+0.1%
Current assets	29/58	€471,655	€404,549	-€67,106	-14.2%
Amounts receivable after more than one year	29	€51,250	€1,250	-€50,000	-97.6%
Other amounts receivable	291	€51,250	€1,250	-€50,000	-97.6%
Stocks and contracts in progress	3	€59,476	€62,187	+€2,711	+4.6%
Stocks	30/36	€59,476	€62,187	+€2,711	+4.6%
Amounts receivable within one year	40/41	€349,638	€316,740	-€32,897	-9.4%
Trade receivables	40	€188,099	€183,970	-€4,130	-2.2%
Other amounts receivable	41	€161,539	€132,771	-€28,768	-17.8%
Cash at bank and in hand	54/58	€8,505	€18,745	+€10,240	+120%
Deferred charges and accrued income	490/1	€2,787	€5,627	+€2,840	+102%
Total equity and liabilities	10/49	€3,683,054	€3,676,908	-€6,147	-0.2%
Equity	10/15	€291,149	€495,288	+€204,139	+70.1%
Contributions	10/11	€940,000	€940,000	=	0.0%
Revaluation surpluses	12	€565,000	€964,000	+€399,000	+70.6%
Reserves	13	€44,750	€44,750	=	0.0%
Non-distributable reserves	130/1	€44,750	€44,750	=	0.0%
Other	1319	€44,750	€44,750	=	0.0%
Profit (loss) carried forward	14	-€1,314,749	-€1,500,970	-€186,221	-14.2%
Investment grants	15	€56,148	€47,508	-€8,640	-15.4%
Provisions and deferred taxes	16	€14,037	€11,877	-€2,160	-15.4%
Deferred taxes	168	€14,037	€11,877	-€2,160	-15.4%
Amounts payable	17/49	€3,377,868	€3,169,742	-€208,126	-6.2%
Amounts payable after more than one year	17	€1,420,754	€1,238,722	-€182,032	-12.8%
Financial debts	170/4	€755,754	€573,722	-€182,032	-24.1%
Other amounts payable	178/9	€665,000	€665,000	=	0.0%
Amounts payable within one year	42/48	€1,953,119	€1,931,021	-€22,098	-1.1%
Current portion of amounts payable after more than one year	42	€189,050	€182,032	-€7,018	-3.7%
Financial debts	43	€310,000	€310,000	=	0.0%
Credit institutions	430/8	€310,000	€310,000	=	0.0%
Trade debts	44	€165,653	€133,578	-€32,075	-19.4%
Suppliers	440/4	€165,653	€133,578	-€32,075	-19.4%
Taxes, remuneration and social security	45	€15,566	€29,188	+€13,621	+87.5%
Taxes	450/3	€11,366	€29,188	+€17,821	+157%
Remuneration and social security	454/9	€4,200	€0	-€4,200	-100%
Other amounts payable	47/48	€1,272,850	€1,276,223	+€3,373	+0.3%
Accrued charges and deferred income	492/3	€3,996	€0	-€3,996	-100%
Non-recurring operating income	76A	€609,241	€0	-€609,241	-100%
Remuneration, social security and pensions	62	€10,359	€244	-€10,115	-97.6%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets	630	€269,919	€260,195	-€9,724	-3.6%
Other operating charges	640/8	€8,794	€46,062	+€37,267	+424%
Non-recurring operating charges	66A	-	€6,111	+€6,111
Gross operating margin	9900	€702,580	€160,014	-€542,565	-77.2%
Operating profit (loss)	9901	€413,508	-€152,597	-€566,105
Financial income	75/76B	€9,237	€8,725	-€512	-5.5%
Recurring financial income	75	€9,237	€8,725	-€512	-5.5%
Financial charges	65/66B	€54,082	€44,294	-€9,788	-18.1%
Recurring financial charges	65	€54,082	€44,294	-€9,788	-18.1%
Profit (loss) for the period before taxes	9903	€368,663	-€188,166	-€556,829
Transfer from deferred taxes	780	€2,160	€2,160	=	0.0%
Income taxes	67/77	€220	€215	-€5	-2.1%
Profit (loss) for the period	9904	€370,603	-€186,221	-€556,824
Profit (loss) for the period to be appropriated	9905	€370,603	-€186,221	-€556,824

ARCHIDUC USIL: value indication

ARCHIDUC USIL: value indication

Position among the sector peers

What moved between 2024 and 2025

Largest movements

Change in the result, 2024 to 2025

Derived cash bridge

Value

Indicative value of the equity

Adjusted equity

Capitalised earnings

Your EBITDA multiple

Limits of the indication

Next steps